New hope for tough thyroid cancers: drug combo trial launches

NCT ID NCT07068542

Recruiting now Disease control Sponsor: Zhejiang Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs, sacituzumab tirumotecan and tislelizumab, in people with advanced thyroid cancer that has stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or help people live longer. About 94 adults with three types of hard-to-treat thyroid cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED THYROID CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma poorly differentiated thyroid gland carcinoma thyroid gland carcinoma thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED THYROID CARCINOMA POORLY DIFFERENTIATED THYROID CARCINOMA RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER

Contacts and locations

Locations

Zhejiang Provincial People's Hospital
RECRUITING

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.